Skip to main content
. Author manuscript; available in PMC: 2020 May 7.
Published in final edited form as: J Am Coll Cardiol. 2019 May 7;73(17):2195–2205. doi: 10.1016/j.jacc.2019.01.074

Table 2.

Candidate heart failure biomarkers based upon DNA-aptamer proteomic results from discarded clinical plasma specimens

Protein (levels in relative fluorescent units) HF
N = 48
No HF
N = 47
p % Difference
Cystatin-C 2272 (1896, 2963) 1434 (1263, 1772) 2.04 × 10−10 58
Renin 1238 (709, 1945) 393 (289, 610) 4.74 × 10−10 215
Thrombospondin-2 21260 (13500, 32150) 9094 (7242, 13680) 9.60 × 10−9 134
Insulin like growth factor binding protein-6 697 (516, 884) 442 (406, 514) 1.46 × 10−8 58
Angiopoietin-2 593 (461, 791) 393 (331, 468) 3.51 × 10−7 51
Interleukin-17 receptor C 1729 (1331, 2329) 1065 (882, 1389) 4.24 × 10−7 62
Kallikrein-11 1866 (1206, 2279) 1073 (901, 1339) 4.58 × 10−7 74
Macrophage colony-stimulating factor-1 2166 (1663, 2733) 1292 (1138, 1553) 6.87 × 10−7 68
Leukotriene A-4 hydrolase 1763 (1165, 2344) 955 (796, 1187) 4.60 × 10−6 85

Values presented at median (25th, 75th percentile) relative fluorescence units. HF = heart failure. Percent difference calculated as the difference in median values between HF cases and controls (HF minus no HF)/no HF. P value from Wilcoxon rank-sum test using a Bonferroni-corrected p-value threshold of 4.42 × 10−5 = 0.05 / 1,129 proteins assayed. The % difference in median values was calculated as 100 x (median RFU in HF cases – median RFU in controls)/median RFU in controls.